The metabolic syndrome (MetS) increases cardiovascular disease (CVD) risk. How MetS increases CVD risk is incompletely understood, but increasing arterial stiffness is one candidate link, which in turn could be explained by (low-grade) inflammation, endothelial dysfunction (ED) or insulin resistance (IR). However, MetSrelated increases in stiffness may not be uniformly distributed over muscular and elastic arteries. Therefore, the purpose of this study was to determine: (1) the associations between the MetS, and muscular and elastic arterial stiffness, and (2) whether any such associations could be explained by inflammation, ED or IR. These questions were addressed in the Hoorn Study. MetS was defined according to the NCEP (National Cholesterol Education Program) criteria. Arterial stiffness was determined by ultrasound, tonometry and echocardiography. Inflammation, ED and IR were estimated by C-reactive protein, flow-mediated vasodilation and the homoeostatic model for the assessment of IR, respectively. The results showed that MetS was associated with both femoral and brachial arterial stiffness, significantly so for the distensibility coefficients and for the femoral compliance coefficient. In the carotid artery and aorta, no particular pattern emerged. Additional adjustment for either inflammation, ED or IR did not materially alter the results. The results therefore indicate that muscular arteries may stiffen preferentially over elastic arteries and that distensibility is affected to a greater extent than compliance, thus maintaining volume compliance over vessel wall stiffening. Additionally, the increase in stiffness was not explained by inflammation, ED or IR and suggests that stiffening of the muscular arteries in MetS may not be the consequence of these phenomena.
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Introduction
The metabolic syndrome (MetS)-a construct defined by the coexistence of central obesity, dyslipidaemia, elevated blood pressure and impaired glucose metabolism-increases the risk of cardiovascular disease (CVD) and type II diabetes. 1, 2 How the MetS is associated with an increased CVD risk is incompletely understood, but one pathway linking the MetS to CVD may be through increasing arterial stiffness. 3 The term arterial stiffness refers to an impairment in the cushioning function of the artery (that is, a diminished ability to convert the pulsatile blood flow from the heart into a steady and continuous stream throughout the arterial tree), which leads to increased systolic blood pressure, left ventricular hypertrophy, impaired coronary perfusion and arterial stiffness-associated CVD (notably, stroke, heart failure and myocardial infarction), 4 and can be measured both locally (at a single location within the artery wall) or regionally (over a prespecified arterial segment, for example, the carotid-femoral tract). Earlier studies on arterial stiffness in the MetS [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] have raised several issues. Firstly, there is some evidence that, in the MetS, increases in arterial stiffness may not be uniformly distributed over muscular (that is, peripheral) and elastic (that is, central) arteries. 7, 8, 13 The interpretation of the literature, however, is hampered by the fact that most studies reported arterial stiffness in only one site [14] [15] [16] or segment, 5, 6, [9] [10] [11] [12] whereas studies that did report on multiple sites 8 or segments 7, 13 showed discordant results. Secondly, the MetS is associated with insulin resistance (IR), a proinflammatory state and endothelial dysfunction (ED), 17 and it has been suggested that these phenomena play an important role in the complex pathobiology of arterial stiffening. 5, [18] [19] [20] This raises the question whether IR, lowgrade inflammation or ED mediate the association between the MetS and arterial stiffness. 7, [21] [22] [23] Finally, several studies 13, [24] [25] [26] suggest that the association with CVD in the MetS may be stronger in women than in men, thus raising the question whether the impact of the MetS on arterial stiffness is also stronger in women than in men. 7, 11, 27 In view of these considerations, the purpose of this study was: (1) to examine in a population-based cohort of elderly individuals the association(s) between the MetS and arterial stiffness of both elastic and muscular arteries; (2) to examine whether any such associations were mediated by low-grade inflammation, IR or ED; and (3) to examine whether any association between the MetS and arterial stiffness is stronger in women than in men.
Methods

Study population
We used data from the 2000 Hoorn Study follow-up examination and the Hoorn Screening Study. Details have been described elsewhere. [28] [29] [30] This population-based cohort consisted of 822 individuals (290 with normal glucose metabolism, 187 with impaired glucose metabolism and 345 with type II diabetes). For this investigation, all those with type II diabetes were excluded. The final study population thus consisted of 477 individuals.
Informed consent
The local ethics committee approved the study and written informed consent was obtained from all participants.
The metabolic syndrome The MetS was defined according to the updated National Cholesterol Education Program (NCEP) definition. 31 This definition diagnoses the MetS when three or more of the following five risk factors are present: (1) systolic blood pressure X130 mm Hg and/or diastolic blood pressure X85 mm Hg or current drug therapy for known hypertension; (2) high-density lipoprotein (HDL) cholesterol o1.03 mmol l À1 in men and o1.29 mmol l À1 in women or current drug treatment for low HDL cholesterol; (3) triglycerides X1.7 mmol l À1 or current drug treatment for hypertriglyceridaemia; (4) fasting plasma glucose X5.6 mmol l À1 or current drug treatment for elevated glucose level and; (5) waist circumference 4102 cm in men and 488 cm in women (that is, the Caucasian cut off levels considering our study population). In addition, the participants were also classified into four groups according to the number of MetS risk factors present (that is, 0, 1, 2 or X3). Finally, we calculated a MetS z-score to take into account the continuous nature of the association between the MetS risk factors and CVD. This MetS z-score was calculated as follows: for each of the individual components of the MetS, a sex-specific z-score was calculated according to the formula ((valueÀsample mean)/sample s.d.)). The resulting five z-scores were then averaged. The highdensity lipoprotein cholesterol was multiplied by -1 to indicate increasing risk with increasing value; the z-scores for systolic and diastolic blood pressure were averaged to estimate overall blood pressure z-score.
Arterial stiffness
The estimates of artery stiffness were determined as described earlier with the use of arterial ultrasonography, echocardiography and radial applanation tonometry 28, 32, 33 according to the following: distensibility-an indicator of local arterial elastic properties:
; compliance-an indicator of local arterial buffering capacity: p(2D Â DD þ DD 2 )/(4 Â DP) in mm 2 kPa À1 ; Young's elastic modulus-an indicator of local intrinsic elastic wall properties: (D/(IMT) Â distensibility) in kPa (where DP stands for local pulse pressure, 34, 35 D for diameter, (DD) for distension and IMT for carotid intima-media thickness); total systemic arterial compliance-an indicator of total arterial buffering capacity-by the exponentialdecay method based on the Windkessel model 36 and the ratio of stroke volume to aortic pulse pressure; 37 aortic augmentation index-an indicator of total stiffness and wave reflection-by the use of a generalized transfer function; 38 and carotid-femoral transit time-an estimate of regional stiffness closely associated with the gold standard estimate of stiffness: pulse wave velocity-by the time delay from the electrocardiograph trigger to 10% of the ascending slope of the distension curve of both arteries subtracted from one another. 39 
Other measurements
We determined health status, medical history, medication use, smoking habits, systolic, diastolic, mean arterial and pulse pressure, glucose, glycated haemoglobin, insulin, serum total, high-density and low-density lipoprotein cholesterol, serum triglycerides, serum creatinine, (micro) albuminuria, body mass index, waist-to-hip ratio, prior CVD and anklebrachial index as described earlier. [28] [29] [30] IR was calculated according to the HOMA (homeostatic model assessment) model. 40 Resting electrocardiograms were coded according to the Minnesota Code. Endothelial function was determined non-invasively by brachial artery ultrasonograpy (endothelium-dependent flow-mediated vasodilation) as described earlier. 41 
Statistical analyses
All analyses were executed with SPSS (version 15.0; Chicago, IL, USA). Multivariate regression analyses were used to analyse the relationship between the MetS and arterial stiffness. The MetS was analysed according to the NCEP definition; according to the number of metabolic risk factors present as dummy variables (0, 1, 2 or X3; in which individuals with 0 risk factors served as reference category); and by the combined z-score.
The analyses were first adjusted for age, sex, mean arterial pressure, prior CVD and lipid-lowering medication (model B). Of note, model B included heart rate and height in case of the augmentation index and the femoral-carotid transit time. The models were then additionally adjusted for high-sensitivity C-reactive protein (model C), ED (model D) and HOMA-IR (homoeostatic model for the assessment of IR) (model E).
After assessment of the main effects, interaction terms were introduced into the models to investigate whether the association between the MetS and arterial stiffness differed between men and women.
P-values o0.05 were considered statistically significant, except for the interaction analyses, in which P-values o0.10 were considered statistically significant.
Results
Of the 477 participants, 11 participants had missing data on arterial stiffness estimates, antropomorphometric or biochemical variables. These participants were excluded from the analyses. The study population for this investigation therefore consisted of 466 individuals except for the analyses of the carotidfemoral transit time, which was available in only 193 individuals. 33 
Baseline characteristics
The clinical and arterial data of the study population according to sex and the presence or absence of the MetS are summarized in the Tables 1 and 2 .
The metabolic syndrome
In the total population, the prevalence of the MetS (X3 risk factors) was 39% (n ¼ 181). According to sex, 36% (n ¼ 82) of all men and 41% (n ¼ 99) of women fulfilled the MetS criteria ( Figure 1 ). 52% of all women met the criterion to consider waist circumference a MetS risk factor, whereas only 27% of all men did ( Figure 1 ). Of all participants, 7% (n ¼ 33) had no MetS risk factors, 26% (n ¼ 124) had one risk factor and 27% (n ¼ 128) had two risk factors (not depicted).
The metabolic syndrome and arterial stiffness The crude associations between the MetS z-score and the stiffness estimates are given in model A (Table 3) . After adjustment for sex, age, mean arterial pressure, prior CVD and lipid-lowering medication the MetS, z-score was associated with both femoral and brachial artery stiffness, significantly so for the femoral and the brachial distensibility coefficient (b (95% CI): À0.82 (À1.24; À0.40); Po0.001 and À0.98 (À1.87; À0.09); P ¼ 0.031, respectively); (Table 3 ) and the femoral compliance coefficient (b (95% CI): À0.06 (À0.10; À0.03); P ¼ 0.001) (model B; Table 3 ). Additional adjustment for either low-grade inflammation (model C), ED (model D) or IR (model E) (estimated by C-reactive protein; flow-mediated vasodilation and the HOMA-IR, respectively) did not materially alter the results for the femoral artery, whereas in the brachial artery, additional adjustment for endothelial function and HOMA-IR, rendered the associations with the MetS statistically nonsignificant. However, HOMA-IR explained approximately 14-31% of the association between the MetS and femoral or brachial artery distensibility coefficient. In the carotid artery and the aorta, no particular pattern emerged with regard to the MetS and arterial stiffness (Table 3) .
Similar results were obtained if the analyses were done with the MetS, defined as either present or absent, or when a number of metabolic risk factors were added to the model as dummy variables (data not shown). However, in the femoral artery, both distensibility and compliance increased with the number of risk factors, whereas this phenomenon was not evident in the brachial artery (Figure 2 ). In the carotid artery and the aorta, no particular pattern could be observed (Figure 3 ). Of note, the bars in Figure 2 and 3 depict the percentage change in the stiffness estimates relative to those without MetS risk factors.
The association between the metabolic syndrome and arterial properties The arterial properties that drive the changes in the local femoral, brachial and carotid stiffness indices are shown in Table 4 . In all three arteries, diameter increased with the MetS, significantly so for the brachial and carotid artery (b (95% CI) 0.12 (0.002; 0.23); P ¼ 0.046 and 0.27 (0.10; 0.43); Po0.001, respectively). Distension decreased in the femoral artery and brachial artery, although significantly so only in the femoral artery (À21.40 (À34.96; À5.84); P ¼ 0.006). Local pulse pressure was significantly increased in the femoral artery (4.18 (1.42; 6.94); P ¼ 0.003). Carotid intima-media thickness was increased in the MetS, although not significantly.
Additional analyses
The association between the MetS and arterial stiffness did not differ importantly between men and women (all P-values for interaction 40.326), except for the femoral compliance coefficient, in which P-value for the interaction between the MetS and sex was 0.09. If we then repeated the femoral compliance analyses separately for men and women, the association between the MetS and femoral arterial stiffness was significantly stronger in men than in women (b (95% CI): À0.11 (À0.43; À0.17); P ¼ 0.001 and À0.04 (À0.08; 0.004); P ¼ 0.073, respectively).
If we replaced, in the combined MetS z-score, the individual z-score for blood pressure for an individual z-score of either systolic or diastolic blood pressure, our results were largely unaltered. However, the association between the MetS and arterial stiffness was somewhat stronger for the combined MetS z-score, in which we used the individual z-score for systolic blood pressure (data not shown). Our results were also similar if we calculated an individual z-score for diastolic blood pressure that took into account the inverse relationship between diastolic blood pressure and arterial stiffness (data not shown).
The results were not materially altered if model B (Table 3) was additionally adjusted for weight, body mass index, smoking, serum creatinine, (micro) albuminuria, homocysteine, total cholesterol, or low-density lipoprotein cholesterol (data not shown). Finally, if we repeated the analyses and replaced the combined MetS z-score by the individual z-scores for either blood pressure, high-density lipoprotein, triacylglycerol, fasting glucose or waist circumference, our results showed that blood pressure, fasting glucose and waist circumference were the strongest determinants of arterial stiffness in the MetS (data not shown).
Discussion
This population-based study examined the association between the MetS and arterial stiffness in elderly individuals, and had three main findings. Firstly, those with the MetS had greater muscular, but not elastic, arterial stiffness as compared with those without the MetS. Secondly, the increase in muscular arterial stiffness was independent of Creactive protein, ED or HOMA-IR for the femoral artery, whereas the results in the brachial artery were rendered statistically nonsignificant after adjustment for ED or HOMA-IR. Nevertheless, HOMA-IR explained 14-31% of the association between the MetS and muscular (brachial and femoral) artery stiffness. Thirdly, the association between the MetS and arterial stiffness was largely similar between men and women.
This study was comprehensive as it examined both local and regional arterial stiffness of both Figure 1 The prevalence of the individual components of the metabolic syndrome in percentages among women (black bars) and men (grey bars) according to the NCEP-ATP III criteria. TG, triglycerides; HDL, high-density lipoprotein cholesterol; BP, blood pressure; MetS, metabolic syndrome. muscular and elastic arteries within the same group of individuals in contrast to most, 5,6,9-12,14-16 but not all, 7, 8, 13 earlier studies, which examined arterial stiffness at only one arterial site [14] [15] [16] or at one arterial segment. 5, 6, [9] [10] [11] [12] 16 Our data suggest that increased arterial stiffness may link the MetS to CVD and is in general agreement with the above studies. In addition, our data supports the observation that muscular arteries-in particular the femoral artery-seem to stiffen preferentially over elastic arteries. 39 However, a study by Ferreira et al. 7, 8 in young adults and a study by Schillaci et al. 13 in middle-aged participants showed the reverse (that is, individuals with the MetS had greater elastic than muscular arterial stiffness). The reason for this discrepancy is not clear. It can, however, be speculated that increasing age plays an important role and (or) that different segments of the arterial tree respond differently to 'metabolic stress' as a consequence of important structural and functional differences between muscular and elastic arteries. 39, 42 Our data would then support the hypothesis that the process of arterial remodelling may favour the preservation of (elastic) compliance, 43 which is in accordance with our observation that the carotid and brachial arterial diameter were significantly increased in the MetS (Table 4) . Nevertheless, peripheral arterial stiffness may be clinically just as important as it has been shown to be closely associated with prevalent peripheral vascular disease, 44, 45 which is a clinically important outcome in the (pre-) diabetic population. Future research will clarify this issue.
The association between the MetS and increased muscular arterial stiffness was independent of C-reactive protein and these findings are in line with Saijo et al., 22 who also showed that the association between the MetS and increased arterial stiffness was not mediated by low-grade inflammation as estimated by C-reactive protein. These findings therefore leave room to speculate that perhaps other inflammatory markers may directly mediate the association between the MetS and arterial stiffness (for example, the adipocytokines interleukin-6 or tumour necrosis factor-a). 19, 22, 46 The latter would be in line with our finding that waist circumference, which is a reflection of visceral adiposity, and in turn is an important source of adipocytokines, was among the strongest determinants of increased arterial stiffness. Alternatively, waist circumference is also an important determinant of IR, and in our study, HOMA-IR explained 8-29% of the association between the MetS and femoral arterial stiffness. This observation draws attention to the role of hyperinsulinaemia, which is known to detrimentally affect the arterial wall through the induction of ED, 21 which may blunt the acute vasodilatory effects of insulin in insulinresistant states. 47 In addition to the above mechanisms, an additional role linking the MetS to increased arterial stiffness may be played by fasting hyperglycaemia through the non-enzymatic glycation of matrix proteins and the accumulation of advanced glycation end products. Advanced glycation end products can form crosslinks in and between the arterial pressure load-bearing elements of the arterial wall, thereby increasing arterial stiffness, and accordingly, the glycation crosslink breaker Alagebrium (formerly known as ALT-711) reduces arterial stiffness. 48 No earlier studies have examined whether the relationship between the MetS and arterial stiffness was mediated by ED, as estimated by brachial flow-mediated dilation. In our study, brachial flowmediated vasodilatation did not mediate the association between the MetS and femoral arterial stiffness, whereas it did in the brachial artery. The latter may be the consequence of measuring both arterial stiffness and flow-mediated dilation at the very same arterial spot in which the interrelation between arterial stiffness and flow-mediated dilation may hamper interpretation. 49 It is, however, important to realize that brachial flow-mediated vasodilation is only one form of ED presumably representing an altered balance between vasodilatory and vasoconstricting substances. 50 Therefore, it cannot be excluded that other forms of ED (for example, estimates of altered vascular matrix remodelling or (leucocyte) permeability) explain, at least partially, the relationship between the MetS and arterial stiffness.
Several studies have suggested that the association between the MetS and (or) type II diabetes and CVD is stronger in women than in men. [24] [25] [26] This could potentially be explained by the observations that women with the MetS had stiffer arteries, 7, 11, 27 greater left ventricular mass and greater impairment of left ventricular function, 51, 52 as compared with their male counterparts. In our study, however, no clear difference existed between men and women with regard to arterial stiffness, despite a single significant interaction term between the MetS and sex for the femoral compliance coefficient. The latter could be a chance finding. Alternatively, the absence of a clear difference between men and women could also be explained by selective mortality of women with the stiffest arteries.
Finally, for this study we used a continuous z-score to investigate the association between MetS The results are presented as b (95% CI) and P-value. All adjusted for sex, age, mean arterial pressure, prior cardiovascular disease and lipidlowering medication.
and arterial stiffness. This approach takes into account the continuous nature of the relationship between MetS traits and CVD, and thereby disregards the erroneous assumption that the increase in CVD risk only starts after a certain cutoff value. Our study had several limitations. Firstly, our results were based upon cross-sectional analyses; therefore, any inferences relating to causality should be made with caution. Secondly, our results were based upon a cohort of white elderly individuals. It remains to be established whether our results can be generalized to other ethnicities and age groups. Thirdly, with regard to the estimates of central stiffness, it is still a matter of debate whether, for example, alterations in augmentation index could occur independently from changes in blood pressure or other measures of stiffness.
3 Future research will clarify this issue. Finally, as stated before, our results could have been influenced by selective mortality, which may have caused us to underestimate the relationship between the MetS and arterial stiffness.
In conclusion, the results from this study show that the MetS is associated with increased muscular, but not elastic, arterial stiffness, in both men and women, independent from low-grade inflammation, ED or IR, and may explain the increased CVD risk in MetS. Future research will help to further disentangle the complex pathophysiology underlying the association between the MetS and increased arterial stiffness.
